Smart patches could save hearts: hospital trial tests continuous monitoring

NCT ID NCT07622485

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a wearable monitoring system (ECG patch, temperature patch, and pulse oximeter) can reduce major heart complications in hospitalized patients with heart disease. About 1500 adults will be monitored either with standard care (vital signs every 4-8 hours) or with the wearable device that sends continuous data and alerts. The goal is to see if catching problems earlier leads to fewer heart attacks, strokes, or other serious events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

thynC Inpatient Monitoring System (wearable device with ECG patch, temperature patch, and pulse oximeter)

What this could lead to

If successful, this could show that continuous wearable monitoring in hospitals helps detect problems earlier and reduces serious heart events like heart attacks or strokes.

What could go wrong

This is a relatively early-stage trial (not yet recruiting) and uses a new device; it may not prove better than standard care, and technical issues or false alarms could occur.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome aortic disorder Arrhythmias, Cardiac atrial fibrillation cardiovascular disorder heart failure peripheral arterial disease third-degree atrioventricular block venous thromboembolism ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Yonsei University Yongin Severance Hospital

    Yongin, Gyeonggi-do, 16995, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••